Entity

Time filter

Source Type

Hammam Sousse, Tunisia

Ben Dhiab M.,Farhat Hached Hospital of Sousse | Ziadi S.,Farhat Hached Hospital of Sousse | Ksiaa F.,Farhat Hached Hospital of Sousse | Louhichi T.,Farhat Hached Hospital of Sousse | And 5 more authors.
Tumor Biology | Year: 2015

Deregulation of the microRNA miR124a by DNA methylation has been implicated in various malignancies, but no study reported its methylation status in Hodgkin lymphoma (HL). We evaluated the methylation of the three loci encoding for miR124a using methylation-specific PCR in 64 HL patients and 15 reactive lymph nodes obtained from patients with nonmalignant diseases. Results were correlated with clinicopathological parameters. Methylation rates of miR124a-1, miR124a-2, and miR124a-3 in HL were 17, 50, and 28 %, respectively. None of the nontumoral samples showed aberrant hypermethylation in any of the miR tested. In HL cases, we found that miR124a-1 methylation correlates with high-risk International Prognostic Score (IPS) (score >3, p = 0.04) and that miR124a-2 methylation was more frequent in children (82.3 %, p = 0.006) and men (63.9 %, p = 0.01). Methylation of miR124a-3 was associated with advanced Ann-Arbor stages (p = 0.007). The survival analysis showed that methylation of at least one of the miR124a genes was associated with shortened event-free survival in univariate (p = 0.03) and multivariate (p = 0.02) analyses. These results suggest that miR124a methylation is associated with aggressive HL disease and may be an interesting factor for predicting treatment response. © 2014, International Society of Oncology and BioMarkers (ISOBM).

Discover hidden collaborations